Teva Recalls Lidocaine Patches Due to Failed Stability Specifications
Teva Pharmaceuticals USA is recalling Lidocaine Patch 5% products because they failed stability specifications. The recall covers 30,382 patches distributed in the United States.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The agency classified this as an FDA Class III recall, which by definition is unlikely to cause adverse health consequences. The source text does not report any illnesses or injuries.
Plain-English summary
Teva Pharmaceuticals USA is recalling Lidocaine Patch 5% (700 mg) products. The recall involves 30,382 patches, specifically NDC 0591-3525-11 and NDC 0591-3525-30. The affected products are identified by Carton Lot Number 1147020B and Patch (Envelope) Lot Number 1147020.
The reason for the recall is that the products failed stability specifications. The source text does not provide further details regarding the specific nature of the stability failure or any reported adverse health events.
The affected products were distributed in the United States. Consumers and healthcare providers should check their inventory for the specific lot numbers listed above and discontinue use of the recalled products.
The recalled product
- Product
- LIDOCAINE (LIDOCAINE)
- Brand
- LIDOCAINE
- Manufacturer
- Teva Pharmaceuticals USA
- Category
- Drug — Topical Anesthetic
- Hazard
- Affected units
- 30,382
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Carton Lot Number:1147020B Patch (Envelope) Lot Number: 1147020
Distribution
Distribution scope not specified by the agency.
Related recalls
Same brand · LIDOCAINE
- HighLidocaine Injection Recall Due to Hair Contamination
FDA (Drugs) · 2026-07-29
- ModerateLidocaine and epinephrine dental cartridges recalled over cracked containers
FDA (Drugs) · 2025-12-24
- ModerateLidocaine Patch 5% Recalled for Typographical Error on Label
FDA (Drugs) · 2023-05-10
- ModerateFDA Recalls Prescription Lidocaine Patch Due to Temperature Exposure
FDA (Drugs) · 2022-06-15
- ModeratePrescription Lidocaine Patches Recalled for Temperature-Related Quality Deviations
FDA (Drugs) · 2022-06-15
Same manufacturer · Teva Pharmaceuticals USA
See all →- ModerateDoxylamine Succinate and Pyridoxine Hydrochloride Tablets Recalled for Failed Dissolution
FDA (Drugs) · 2022-02-09
- LowPrescription Drug Recall: Mimvey Mislabeling by Teva Pharmaceuticals
FDA (Drugs) · 2022-02-09
- ModerateTretinoin Capsules 10 mg Recalled for Failed Dissolution Specifications
FDA (Drugs) · 2022-02-09
- LowMimvey Estradiol/Norethindrone Prescription Drug Mislabeling Recall
FDA (Drugs) · 2022-02-09
- ModerateBrinzolamide Ophthalmic Suspension recalled for defective container caps
FDA (Drugs) · 2022-01-26
Same hazard · stability failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateVasocaine lidocaine spray recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateZone 2 lidocaine cream recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateZone 1 lidocaine cream recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateCiclopirox shampoo recalled after failing impurity specifications at eighteen months
FDA (Drugs) · 2025-12-24